Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-10-20
Target enrollment:
Participant gender:
Summary
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend
Nab-paclitaxel, Gemcitabine and modified Folfirinox as the first-line chemotherapeutic
regimen. Studies have shown that sequential chemotherapeutic regimen can effectively delay
the drug resistance and improve the effect of chemotherapy. Here investigators intend to
assess the effect of sequential treatment with Nab-paclitaxel plus Gemcitabine and modified
Folfirinox as neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University